CHENGDU, China, Feb. 5, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in…
In March 17, 2008, QLT announced that the US Food and Drug Administration (FDA) removed the label restrictions for its acne product, Aczone(TM) (see also News section). Following this announcement, QLT's stock surged by 55%.
QLT reported its financial position for the full-year 2007. Visudyne(R) sales for the full year represented a decrease of 39.3% over annual sales in 2006; however, Eligard(R) sales increased almost 50% from the prior year.
